173 related articles for article (PubMed ID: 36088292)
1. Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Wendler J; Fox CP; Valk E; Steinheber C; Fricker H; Isbell LK; Neumaier S; Okosun J; Scherer F; Ihorst G; Cwynarski K; Schorb E; Illerhaus G
BMC Cancer; 2022 Sep; 22(1):971. PubMed ID: 36088292
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
3. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G
BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912
[TBL] [Abstract][Full Text] [Related]
4. Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trial.
Isbell LK; Uibeleisen R; Friedl A; Burger E; Dopatka T; Scherer F; Orban A; Lauer E; Malenica N; Semenova I; Vreden A; Valk E; Wendler J; Neumaier S; Fricker H; El Rabih AAH; Gloggengießer C; Hilbig D; Bleul S; Weis J; Gmehlin D; Backenstrass M; Wirtz S; Ihorst G; Finke J; Illerhaus G; Schorb E
BMC Cancer; 2023 Aug; 23(1):767. PubMed ID: 37596517
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
6. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
Illerhaus G; Kasenda B; Ihorst G; Egerer G; Lamprecht M; Keller U; Wolf HH; Hirt C; Stilgenbauer S; Binder M; Hau P; Edinger M; Frickhofen N; Bentz M; Möhle R; Röth A; Pfreundschuh M; von Baumgarten L; Deckert M; Hader C; Fricker H; Valk E; Schorb E; Fritsch K; Finke J
Lancet Haematol; 2016 Aug; 3(8):e388-97. PubMed ID: 27476790
[TBL] [Abstract][Full Text] [Related]
10. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
12. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Kasenda B; Schorb E; Fritsch K; Finke J; Illerhaus G
Ann Oncol; 2012 Oct; 23(10):2670-2675. PubMed ID: 22473593
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; Celico C; Falautano M; Nonis A; La Rosée P; Binder M; Fabbri A; Ilariucci F; Krampera M; Roth A; Hemmaway C; Johnson PW; Linton KM; Pukrop T; Gørløv JS; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Zanni M; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Thurner L; Cabras G; Pennese E; Ponzoni M; Deckert M; Politi LS; Finke J; Ferranti A; Cozens K; Burger E; Ielmini N; Cavalli F; Zucca E; Illerhaus G;
Leukemia; 2022 Jul; 36(7):1870-1878. PubMed ID: 35562406
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.
Bairey O; Lebel E; Buxbaum C; Porges T; Taliansky A; Gurion R; Goldschmidt N; Shina TT; Zektser M; Hofstetter L; Siegal T
Hematol Oncol; 2023 Dec; 41(5):838-847. PubMed ID: 37403752
[TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
16. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
Cho H; Chang JH; Kim YR; Kim SJ; Chung H; Park H; Lee JY; Jang JE; Kim Y; Kim SH; Yang WI; Suh CO; Cheong JW; Min YH; Kim JS
Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207
[TBL] [Abstract][Full Text] [Related]
17. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.
Houillier C; Taillandier L; Dureau S; Lamy T; Laadhari M; Chinot O; Moluçon-Chabrot C; Soubeyran P; Gressin R; Choquet S; Damaj G; Thyss A; Abraham J; Delwail V; Gyan E; Sanhes L; Cornillon J; Garidi R; Delmer A; Tanguy ML; Al Jijakli A; Morel P; Bourquard P; Moles MP; Chauchet A; Gastinne T; Constans JM; Langer A; Martin A; Moisson P; Lacomblez L; Martin-Duverneuil N; Delgadillo D; Turbiez I; Feuvret L; Cassoux N; Touitou V; Ricard D; Hoang-Xuan K; Soussain C;
J Clin Oncol; 2019 Apr; 37(10):823-833. PubMed ID: 30785830
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
